As expected, wild-type BoNT/X cleaved the VAMP1 fusion but showed no detectable activity on the procaspase-1 substrate (Extended Data Fig
R.VahlT
When a peptide meets its receptor, its like a text message to the cell: Repair here, Make more collagen, or Turn down inflammation. Many therapeutic peptides are synthetic or lab-refined versions of molecules your body already produces, so they tend to work by amplifying or fine-tuning the bodys own signals rather than overriding them
Patients need to be on the 2.4 mg maintenance dose for a minimum of four weeks before a provider can consider advancing to 7.2 mg
To overcome this limitation, scientists have developed GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide, tilpotide, etc., which extend the half-life to the weekly formulation level through structural modification, achieving sustained regulation